intellia
therapeutics
present
chardan
virtual
annual
genetic
medicines
conference
cambridge
globe
newswire
intellia
therapeutics
nasdaq
ntla
leading
genome
editing
company
focused
developing
curative
therapeutics
using
crispr
technology
vivo
ex
vivo
present
chardan
virtual
annual
genetic
medicines
conference
monday
october
et
live
webcast
intellia
presentation
accessible
events
presentations
page
investors
media
section
company
website
access
webcast
please
log
approximately
minutes
prior
start
time
ensure
adequate
time
software
downloads
may
required
replay
webcast
available
intellia
website
approximately
days
following
live
event
intellia
therapeutics
intellia
therapeutics
leading
genome
editing
company
focused
developing
proprietary
curative
therapeutics
using
crispr
system
intellia
believes
crispr
technology
potential
transform
medicine
permanently
editing
genes
human
body
single
treatment
course
improved
cell
therapies
treat
cancer
immunological
diseases
replace
patients
diseased
cells
combination
deep
scientific
technical
clinical
development
experience
along
leading
intellectual
property
portfolio
puts
intellia
unique
position
unlock
broad
therapeutic
applications
crispr
technology
create
new
class
therapeutic
products
learn
intellia
therapeutics
crispr
follow
us
twitter
intelliatweets
intellia
contacts
investors
lina
li
associate
director
investor
relations
media
jennifer
mound
smoter
senior
vice
president
external
affairs
communications
